DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

Eden vs Fifty 410: November 2026 prices compared

As of November 20, 2026, from each program’s own page: on compounded tirzepatide, month to month and all-in, Eden charges $129 a month and Fifty 410 $199 per 28-day cycle: $1,548 against $2,587 for a year, so Eden costs $1,039 less over a year.

Released · Last reviewed · how we verify

On compounded semaglutide, month to month and all-in, Eden charges $99 a month and Fifty 410 $199 per 28-day cycle: $1,188 against $2,587 for a year, so Eden costs $1,399 less over a year.

Eden and Fifty 410, measure by measure

Eden and Fifty 410 side by side, from each program’s own page read November 20, 2026 (all-in: medication plus any required recurring fee, before tax)
MeasureEdenFifty 410
Tirzepatide, month to month$129 (per month)$199 (per 28-day cycle)
Tirzepatide, lowest printed$129 (every month)$149.50 (8-week program at $299, not in all states)
Semaglutide, month to month$99 (per month)$199 (per 28-day cycle)
Semaglutide, lowest printed$99 (every month)$199 (4-week program)
Dose pricingsame price at every dosepriced by dose or not stated
Membership or program feenonenone
Computed score34.3 of 40 (position 3 of 27)23.5 of 40 (position 8 of 27)
FDA warning letters728279 (2026-06-08)721481 (2026-02-20)
November 20 readfirst-party readfirst-party read, changed

Strengths and limitations: which fits whom

Eden prints one price at every dose with no membership, so a dose increase does not change the bill. Fifty 410 bills every 28 days, which adds a 13th charge to the year. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.

What changed since August

The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.

What changed since the August 2026 capture (maintenance-dose all-in figure then; month-to-month all-in figure read November 20, 2026)
ProgramMedicationAugust 5–10, 2026November 20, 2026
Edentirzepatide$408$129
Edensemaglutide$198$99
Fifty 410tirzepatide—$199
Fifty 410semaglutide—$199

Regulatory record

FDA’s warning-letter index lists warning letter 728279 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to Eden; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 721481 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to Fifty 410; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.

Check Eden’s current prices ↗
Check Fifty 410’s current prices ↗

Frequently asked

Which is cheaper, Eden or Fifty 410?

On compounded tirzepatide, month to month and all-in, Eden charges $129 a month and Fifty 410 $199 per 28-day cycle: $1,548 against $2,587 for a year, so Eden costs $1,039 less over a year. On compounded semaglutide, month to month and all-in, Eden charges $99 a month and Fifty 410 $199 per 28-day cycle: $1,188 against $2,587 for a year, so Eden costs $1,399 less over a year.

Do Eden and Fifty 410 charge a membership fee?

Eden: no membership fee; Fifty 410: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.

Are Eden and Fifty 410 medications FDA-approved?

Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.

Eden recordEden alternativesFifty 410 recordAll head-to-headsRankingsPrice database

Sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.